FNC-nicotine: Does Sweet Taste Potentiate Nicotine Cue Reactivity?

Sponsor
Yale University (Other)
Overall Status
Completed
CT.gov ID
NCT02499757
Collaborator
National Institute on Drug Abuse (NIDA) (NIH)
15
1
4
6
2.5

Study Details

Study Description

Brief Summary

The investigators' aim is to test the prediction that sweet taste perception enhances the ability of nicotine to induce neural plastic changes in brain reward circuits to increase the saliency, liking and brain reactivity to the sight and vaporized flavor of electronic cigarettes (e-cigarettes).

Condition or Disease Intervention/Treatment Phase
  • Device: flavor and sweetener
  • Device: flavor and nicotine
  • Device: flavor, nicotine and sweetener
  • Device: flavor
Phase 1

Detailed Description

Alternative tobacco products are becoming increasingly available in the US market and are promoted as potentially less deleterious compared to cigarettes. These products are increasing in usage as either a substitution for cigarette smoking or in addition to smoking. One particular appeal is that they often combine nicotine with sweet taste and flavors, which are themselves reinforcing. The primary goal of this project is to determine if sweet taste can potentiate the reinforcing properties of nicotine. Similar to nicotine, cues predicting the availability of carbohydrates can stimulate intake, even in the absence of hunger. The investigators have developed a novel flavor-nutrient conditioning paradigm to study the reinforcing properties of carbohydrates. Novel flavors are paired with 0 or 113 kcal carbohydrate and increases in flavor-cue reactivity (change in liking and brain response) when later sampled in the absence of the carbohydrate provide a measure of the reinforcing potency. For smokers, the aroma of tobacco is a potent cue that can promote smoking behavior. Using a modified version of our conditioning paradigm, our specific aim is to test the prediction that sweet taste perception enhances the ability of nicotine to induce neural plastic changes in brain reward circuits to increase the saliency, liking and brain reactivity to the sight and vaporized flavor of electronic cigarettes (e-cigarettes). Participants will smoke e-cigarettes that contain nicotine and an unsweetened vaporized flavor, nicotine and a sweet vaporized flavor or only a sweet vaporized flavor (no nicotine). The investigators predict that response in the nucleus accumbens and hypothalamus to the sight and vaporized flavor of the e-cigarette that was paired with nicotine and sweet taste will be greater than the responses to the sight and vaporized flavors associated with the other e-cigarettes. The investigators further predict that liking and wanting will increase more for the sight and vaporized flavor associated with both nicotine and sweet taste. This finding would provide strong evidence that sweet taste potentiates the reinforcement potency of nicotine and could therefore promote use.

Study Design

Study Type:
Interventional
Actual Enrollment :
15 participants
Allocation:
Non-Randomized
Intervention Model:
Factorial Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Basic Science
Official Title:
Does Sweet Taste Potentiate Nicotine Cue Reactivity?
Study Start Date :
May 1, 2015
Actual Primary Completion Date :
Nov 1, 2015
Actual Study Completion Date :
Nov 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: flavor and sweetener

E-cigarette with a novel flavor and sweetener added

Device: flavor and sweetener
maltol added as sweetener to e-cigarette with flavor

Experimental: flavor and nicotine

E-cigarette with a novel flavor and 12 mg nicotine added

Device: flavor and nicotine
12 mg of nicotine added to e-cigarette with flavor

Experimental: flavor, nicotine and sweetener

E-cigarette with a novel flavor, sweetener, and 12 mg nicotine added

Device: flavor, nicotine and sweetener
12 mg nicotine and maltol (sweetener) added to e-cigarette with flavor

Experimental: flavor

E-cigarette with a novel flavor: without a sweetener and 12 mg nicotine added

Device: flavor
flavored e-cigarette stand alone without added nicotine and maltol (sweetener)

Outcome Measures

Primary Outcome Measures

  1. Change from Baseline on Rating: Liking [2 days]

    At baseline and 2 days post exposure, subjects will rate 'liking' using the general Labeled Hedonic Scale (LHS). The LHS is a vertical line scale with quasi-logarithmic spaced, with the label 'most imaginable dislike' in the bottom to 'most imaginable like' in the top, with the label 'neutral' in the middle (recoded to range of -100 to +100).

Secondary Outcome Measures

  1. percent signal change of nucleus accumbens from fMRI [on average 2 weeks]

    brain response in nucleus accumbens and hypothalamus (in percent signal

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • right handed

  • non-daily smoker

  • english speaking

Exclusion Criteria:
  • serious or unstable medical illness (e.g., cancer);

  • past or current history of alcoholism or consistent drug use;

  • current and history of major psychiatric illness as defined by the DSM-IV criteria including eating disorders,

  • medications that affect alertness (e.g., barbiturates, benzodiazepines, chloral hydrate, haloperidol, lithium, carbamazepine, phenytoin, etc.) and any psychoactive drugs or anti-obesity agents;

  • history of major head trauma with loss of consciousness;

  • ongoing pregnancy;

  • known taste or smell dysfunction;

  • a diagnosis of diabetes;

  • any known allergies or sensitivity, including to food, vapors or odors;

  • pregnant or nursing women,

  • history of metalworking, injury with shrapnel or metal slivers, and major surgery;

  • history of pacemaker or neurostimulator implantation m) asthma, chronic obstructive pulmonary disease, bronchitis or any other lung disease.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The John B Pierce Laboratory New Haven Connecticut United States 06519

Sponsors and Collaborators

  • Yale University
  • National Institute on Drug Abuse (NIDA)

Investigators

  • Principal Investigator: Dana M Small, The John B. Pierce Laboratory

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT02499757
Other Study ID Numbers:
  • 1408014434
  • P50DA036151
First Posted:
Jul 16, 2015
Last Update Posted:
Mar 9, 2020
Last Verified:
Mar 1, 2020
Keywords provided by Yale University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 9, 2020